Evidence map›Paper›PMID 30919165›Full record

ReviewCurrent oncology reports2019

Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.

Gargi Kothari, Piet Ost, Patrick Cheung, Pierre Blanchard, Alison C Tree, Nicholas J van As, Simon S Lo, Drew Moghanaki, Andrew Loblaw, Shankar Siva

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 6 countries.

Gargi KothariSir Peter MacCallum Department of Oncology, University of Melbourne, 305 Grattan Street, Peter MacCallum Cancer Center, Melbourne, Victoria, 3000, Australia.
Piet OstDepartment of Radiation Oncology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
Patrick CheungDepartment of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, 2075 Bayview Ave TG 260, Toronto, ON, M4N 3M5, Canada.
Pierre BlanchardGustave-Roussy, Radiotherapy Department, Paris-Saclay University, 114 Rue Edouard Vaillant, F-94800, Villejuif, France.
Alison C TreeRoyal Marsden NHS Foundation Trust and the Institute of Cancer Research, 203 Fulham Road, Chelsea, London, SW3 6JJ, UK.
Nicholas J van AsRoyal Marsden NHS Foundation Trust and the Institute of Cancer Research, 203 Fulham Road, Chelsea, London, SW3 6JJ, UK.
Simon S LoDepartment of Radiation Oncology, University of Washington School of Medicine, 1959 Pacific Street, Seattle, WA, 98195, USA.
Drew MoghanakiHunter Holmes McGuire VA Medical Center, Virginia Commonwealth University, 1201 Broad Rock Boulevard, Richmond, VA, 23249, USA.
Andrew LoblawDepartment of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, 2075 Bayview Ave TG 260, Toronto, ON, M4N 3M5, Canada.
Shankar SivaSir Peter MacCallum Department of Oncology, University of Melbourne, 305 Grattan Street, Peter MacCallum Cancer Center, Melbourne, Victoria, 3000, Australia. Shankar.Siva@petermac.org.
Institute of Cancer Research · GBUniversity of Toronto · CAGhent University Hospital · BEHunter Holmes McGuire VA Medical Center · USInstitut Gustave Roussy · FRPeter MacCallum Cancer Centre · AUUniversity of Melbourne · AUUniversity of Washington · US

Funding

Department of Health
6 · The paper itself

Abstract

purpose of reviewSystemic therapy for patients with hormone-sensitive oligometastatic prostate cancer is non-curative and associated with toxicities. Meanwhile, this population presents unique clinical opportunities to improve outcomes, including the demonstrated benefits of radiotherapy to the primary tumor or oligometastatic sites. RECENT

findingsRecently published randomized studies have demonstrated benefits with the addition of radiotherapy to the primary disease or metastatic lesions in patients with synchronous or metachronous disease. The introduction of novel PET imaging has improved the sensitivity and specificity for detecting metastatic disease and provides an opportunity to better select patients who will benefit from local therapy. The data presented in this review supports revisiting practice guidelines for patients with hormone-sensitive metastatic prostate cancer, particularly in relation to the role of radiotherapy to the primary tumor and sites of oligometastatic disease. Future trials will aim to further establish the role of metastasis-directed therapies in metachronous, synchronous, and castrate-resistant disease.

Indexed as

Androgen AntagonistsCombined Modality TherapyHumansMaleNeoplasm MetastasisPositron-Emission TomographyProstatic NeoplasmsRadiosurgeryRadiotherapy, Image-GuidedTreatment OutcomeAndrogen AntagonistsMetastasis directed therapyOligometastasesProstate cancerSBRT

Identifiers

PMID30919165
OpenAlexW2924849165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.